Is Sermorelin Legal in Wisconsin?

The Short Answer on Sermorelin's Legal Status in Wisconsin

Sermorelin is legal in Wisconsin for adults who obtain it through a licensed physician's prescription and a compliant compounding pharmacy. No Wisconsin statute specifically bans sermorelin, and no DEA schedule restricts it. The key legal constraints come from federal FDA rules governing how compounding pharmacies may prepare it, not from any state-level prohibition.

Because the original branded product Geref was voluntarily withdrawn from the U.S. Market by Serono in 2008 (not due to safety concerns), no finished drug approval currently exists for sermorelin. That absence means the molecule can only reach patients legally via the compounding pathway described below.

Why There Is No Wisconsin-Specific Sermorelin Law

Wisconsin does not maintain a separate peptide registry or peptide-specific statute. State law governs pharmacy practice broadly under Wisconsin Statutes Chapter 450, and the Wisconsin Pharmacy Examining Board sets dispensing standards. Within that framework, compounded drugs, including peptides such as sermorelin, are permissible as long as they satisfy both state pharmacy rules and federal compounding law. The practical legal ceiling is federal, not state.

The DEA Schedule Question

Sermorelin is a 29-amino-acid peptide analogue of growth hormone-releasing hormone (GHRH). It does not appear on any DEA Schedule I through V list. A prescriber does not need a special DEA waiver to prescribe it, and a pharmacy does not need a Schedule II vault to store it. This distinguishes sermorelin sharply from controlled anabolic agents such as testosterone cypionate (Schedule III) or human growth hormone itself, which carries its own federal use restrictions under 21 U.S.C. § 333(e).

Federal FDA Framework: The Rule That Actually Governs Sermorelin Access

The FDA's regulatory position on sermorelin is the single most consequential legal factor for Wisconsin residents. Understanding it correctly prevents both unnecessary alarm and reckless non-compliance.

503A vs. 503B: Which Pharmacy Can Dispense Sermorelin?

The Drug Quality and Security Act of 2013 created two distinct compounding pathways:

503A pharmacies are traditional compounding pharmacies that prepare drugs for individual patients based on a specific prescription from a licensed practitioner. They operate primarily under state pharmacy board oversight with FDA oversight layered on top. A 503A pharmacy in Wisconsin, or one licensed to ship into Wisconsin from another state, may legally compound sermorelin acetate when:

1. A valid, patient-specific prescription exists from a Wisconsin-licensed (or telehealth-licensed) prescriber.
2. The bulk sermorelin API (active pharmaceutical ingredient) comes from an FDA-registered facility.
3. The compounded product is not a copy of a commercially available FDA-approved drug. Because Geref was withdrawn and no current NDA is active, this condition is met.

503B outsourcing facilities are larger operations that may produce drugs in bulk without patient-specific prescriptions but must register with the FDA and comply with current Good Manufacturing Practice (cGMP) standards. Sermorelin's inclusion on the FDA's bulk substances list for 503B use has faced regulatory uncertainty. Wisconsin clinics that order sermorelin in bulk from a 503B facility should verify that the facility holds current FDA registration and that sermorelin appears on the approved bulk substances list at the time of order. The FDA updates this list periodically, and clinicians should check FDA's current 503B bulk substances list before each formulary decision.

The Bulk Substances List and What "Nominated" Means

The FDA has published two lists relevant to 503B facilities: a positive list of bulk substances that may be used and a list under evaluation. Sermorelin has appeared in nominations to the 503B bulk list. Being "nominated" does not mean approved. A 503A pharmacy filling a patient-specific prescription operates under somewhat different rules from a 503B outsourcing facility and generally has a clearer compounding pathway for sermorelin today. Patients and providers in Wisconsin should confirm the current status directly with their chosen pharmacy, since FDA guidance in this area has evolved and may continue to change.

The FDA's Office of Pharmaceutical Quality publishes updated compounding guidance at fda.gov/drugs/human-drug-compounding.

The "Research Use Only" Problem

Sermorelin vials sold online without a prescription and labeled "research use only" (RUO) or "not for human use" occupy a genuinely gray legal area. The label language does not create a legal exemption for human administration. Purchasing, possessing, and self-administering an RUO product without a prescription may violate federal law under the Federal Food, Drug, and Cosmetic Act (FD&C Act) section 503(b), which requires a prescription for drugs intended for human use that are not safe for self-medication. Wisconsin residents who obtain sermorelin this way are not protected by any state statute that overrides that federal requirement.

Wisconsin State Pharmacy and Medical Practice Law

Wisconsin Pharmacy Examining Board Standards

The Wisconsin Pharmacy Examining Board, operating under the Department of Safety and Professional Services (DSPS), licenses both pharmacies and pharmacists in the state. A compounding pharmacy dispensing sermorelin to a Wisconsin patient must hold an active Wisconsin pharmacy permit or be licensed as a non-resident pharmacy shipping into Wisconsin. Wisconsin Administrative Code Phar 7 governs non-sterile compounding, and sterile compounding, which applies to injectable sermorelin, is governed by Phar 8 and incorporates USP Chapter 797 standards for sterile preparation. Any pharmacy compounding injectable sermorelin for Wisconsin residents should demonstrate USP 797 compliance.

Prescriber Requirements in Wisconsin

Any physician (MD or DO), nurse practitioner, or physician assistant licensed in Wisconsin may prescribe sermorelin within the scope of their practice. Wisconsin does not restrict peptide prescribing to endocrinologists or any other specialty. Telehealth prescribers must hold a Wisconsin license or qualify under applicable interstate compact provisions. The Ryan Haight Online Pharmacy Consumer Protection Act requires at least one prior in-person or telemedicine evaluation before a controlled substance may be prescribed via telehealth, but sermorelin is not a controlled substance, so that specific restriction does not apply. Standard telehealth prescribing rules under Wisconsin law and DSPS guidance do apply to the patient-provider relationship.

Medical Practice Act Considerations

Wisconsin's Medical Practice Act, Wis. Stat. § 448.01 et seq., permits licensed physicians to prescribe off-label treatments when clinically justified. Because sermorelin has no current FDA-approved indication (Geref was approved for pediatric growth hormone deficiency before its withdrawal), all adult prescribing is technically off-label. Off-label prescribing is lawful and common in endocrinology. The FDA does not regulate the practice of medicine, and Wisconsin's medical board does not prohibit off-label prescribing when supported by reasonable clinical judgment.

Clinical Profile of Sermorelin: What Wisconsin Patients Should Know Before Requesting a Prescription

Mechanism of Action

Sermorelin acetate is a synthetic 29-amino-acid fragment corresponding to the N-terminal portion of endogenous GHRH(1-44). It binds to GHRH receptors in the anterior pituitary and stimulates pulsatile release of endogenous growth hormone (GH). Because it amplifies the body's own GH pulses rather than introducing exogenous recombinant GH, the resulting IGF-1 increases tend to stay within physiologic ranges. This feature is one reason clinicians view it as a more controllable option than direct GH injections. A 2001 study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that GHRH analogue administration produced measurable increases in GH secretion in older adults with relative GH deficiency (NCBI, PMID 11701709).

Evidence Base

Sermorelin's clinical evidence predates many modern peptide trials. The original Geref NDA was supported by controlled pediatric studies. In adult populations, the evidence base is smaller but real:

• A double-blind, placebo-controlled trial by Corpas et al. (1992) found that 3 months of nightly GHRH(1-29) administration in healthy older men (mean age 68) increased 24-hour GH secretion by approximately 2.5-fold compared to placebo (NCBI, PMID 1522230).
• A 6-month randomized trial published in the Journal of the American Geriatrics Society (Vittone et al., 1997) showed that GHRH(1-29) treatment in older adults significantly raised IGF-1 levels and improved sleep quality metrics without the adverse event profile associated with pharmacologic GH doses (PubMed PMID 9329484).

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults states: "We recommend against making a diagnosis of GHD based on a single low IGF-1 value in a patient without other pituitary deficiencies," a principle that directly informs responsible sermorelin prescribing in Wisconsin (Endocrine Society Guidelines).

Standard Dosing Protocol

Compounded sermorelin is most commonly prepared as 2 mg/mL to 5 mg/mL solutions for subcutaneous injection. Typical starting doses range from 200 mcg to 500 mcg administered subcutaneously at bedtime to align with the physiologic nocturnal GH pulse. Protocols typically run 3 to 6 months before reassessment of IGF-1 levels. Some providers use sermorelin 5 days on, 2 days off to preserve pituitary receptor sensitivity, though the evidence for this specific scheduling is observational rather than from a randomized controlled trial.

Side Effects and Contraindications

Common side effects include injection-site redness (reported in up to 17% of subjects in controlled trials), flushing, and transient headache. Serious adverse events are rare at physiologic doses. Contraindications include active malignancy, because GH axis stimulation may promote tumor growth, and known hypersensitivity to GHRH or sermorelin acetate. The FDA label for the original Geref product listed these contraindications, and compounding pharmacies and prescribers generally carry them forward as clinical standards of practice.

How to Get Sermorelin Legally in Wisconsin: A Step-by-Step Path

Getting sermorelin legally in Wisconsin follows a clear sequence. Skipping any step introduces legal or safety risk.

Step 1: Establish Care With a Licensed Wisconsin Prescriber

Schedule a consultation with a physician, NP, or PA licensed in Wisconsin who has experience in hormone optimization or endocrinology. Telehealth clinics serving Wisconsin may conduct this visit via video. The prescriber must evaluate your clinical picture, not simply fill out a form.

Step 2: Obtain Baseline Laboratory Testing

A responsible prescriber will order at minimum:

• Serum IGF-1 (insulin-like growth factor 1)
• Fasting glucose and HbA1c (sermorelin modestly affects insulin sensitivity)
• A thyroid panel (untreated hypothyroidism blunts GH response)
• CBC and metabolic panel

Some providers also order a GH stimulation test if IGF-1 is borderline. Labs should be drawn before any peptide is initiated.

Step 3: Receive a Patient-Specific Prescription

If the prescriber determines sermorelin is clinically appropriate, they issue a written prescription specifying the compound, dose, concentration, volume, and route. This prescription is what authorizes a 503A pharmacy to compound and dispense the product.

Step 4: Use a USP 797-Compliant 503A Compounding Pharmacy

Your prescriber may direct the prescription to a specific pharmacy, or you may request a pharmacy of your choice. Confirm the pharmacy:

• Holds an active Wisconsin permit or non-resident pharmacy license.
• Compounds sterile injectables under USP 797 conditions.
• Sources API from an FDA-registered supplier.
• Provides a certificate of analysis (CoA) for each batch.

Step 5: Follow the Prescribed Protocol and Retest

Adherence to the prescribed protocol and follow-up lab testing (typically IGF-1 at 8 to 12 weeks) is the standard of care. Dose adjustments should be made by the prescriber based on lab results and symptom response, not by the patient independently.

What Makes Sermorelin Access Legally Risky in Wisconsin

Understanding the legal boundaries helps Wisconsin residents avoid mistakes that create genuine legal exposure.

Importing without a prescription. Importing sermorelin from international online pharmacies without a U.S. Prescription violates the FD&C Act. U.S. Customs may seize such shipments, and the FDA has issued warning letters to domestic distributors selling peptides without complying with compounding law.

Using a prescriber who does not evaluate you. A prescription issued without any clinical evaluation, sometimes called a "rubber stamp" prescription by enforcement agencies, does not provide legal cover under Wisconsin medical practice law or federal law. The prescriber must document clinical justification.

Buying from a pharmacy not licensed to ship into Wisconsin. An out-of-state compounding pharmacy must hold a Wisconsin non-resident pharmacy license (or operate under applicable reciprocity) to legally dispense to Wisconsin addresses. This is a common compliance gap in online peptide prescribing. Wisconsin DSPS maintains a license verification tool at dsps.wi.gov.

Administering to someone else without a prescription in their name. A prescription is patient-specific. Sharing compounded sermorelin violates federal law regardless of intent.

Telehealth Access to Sermorelin in Wisconsin

Wisconsin participated in expanded telehealth prescribing during and after the COVID-19 public health emergency. As of the date of this article's review, Wisconsin telehealth rules allow a licensed provider to establish a patient-provider relationship via synchronous video visit and subsequently prescribe non-controlled substances including compounded peptides. Because sermorelin is not a controlled substance, the additional prescribing restrictions that apply to controlled substances via telehealth do not restrict sermorelin access. The provider still must conduct a clinically adequate evaluation and document it in the medical record.

HealthRX connects Wisconsin patients with board-certified physicians experienced in GH axis evaluation and peptide therapy. All prescriptions are issued only after a full clinical review and baseline labs. Compounded sermorelin is dispensed through 503A pharmacies licensed to serve Wisconsin.

Frequently Asked Questions